GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CMG Pharmaceutical Co 058820.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

3,820

-0.78%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩105.23bn

FY2016FY2025

Net income

−₩10.08bn

FY2016FY2025

Free cash flow

−₩44.03bn

FY2016FY2025

Shareholders' equity

₩201.55bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩105.23bn₩99.10bn₩93.91bn₩82.20bn₩69.48bn₩64.46bn₩58.62bn₩49.86bn₩41.54bn₩32.97bn
Research and development₩1.07bn₩1.45bn₩2.18bn₩3.31bn₩3.41bn₩3.09bn₩2.12bn₩777.8m₩1.80bn₩1.41bn
Operating income−₩3.69bn₩2.51bn₩7.10bn₩2.65bn₩3.20bn₩554.2m₩2.51bn₩2.45bn₩1.54bn₩1.64bn
Net income−₩10.08bn₩2.69bn₩6.46bn−₩388.1m₩3.17bn₩215.0m₩3.05bn₩6.07bn₩2.83bn₩1.73bn
Diluted earnings per share-68.1619.4046.48-2.7922.791.5521.9751.89221.1414.78

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩305.96bn₩303.44bn₩242.10bn₩213.26bn₩199.17bn₩195.36bn₩192.24bn₩114.38bn₩109.57bn₩110.98bn
Cash and short-term investments—₩76.79bn₩68.83bn₩77.81bn₩90.34bn₩109.78bn₩119.57bn₩54.46bn₩57.05bn₩59.16bn
Total liabilities₩104.41bn₩113.89bn₩51.87bn₩28.31bn₩14.47bn₩14.22bn₩12.08bn₩10.40bn₩11.62bn₩9.87bn
Debt—₩79.96bn₩26.12bn₩6.71bn₩510.1m₩491.0m₩286.0m———
Shareholders' equity₩201.55bn₩189.54bn₩190.23bn₩184.95bn₩184.70bn₩181.13bn₩180.16bn₩103.98bn₩97.94bn₩101.11bn
Shares outstanding148m139m139m139m139m139m139m117m13m117m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩11.02bn₩290.1m₩3.91bn₩4.94bn₩5.63bn₩2.94bn₩2.82bn₩886.8m₩1.95bn₩2.31bn
Capital spending−₩33.01bn−₩31.75bn−₩15.25bn−₩10.31bn−₩3.95bn−₩9.65bn−₩8.18bn−₩2.55bn−₩760.6m−₩799.0m
Free cash flow−₩44.03bn−₩31.46bn−₩11.34bn−₩5.37bn₩1.68bn−₩6.71bn−₩5.35bn−₩1.66bn₩1.19bn₩1.51bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩28.26bn₩25.52bn₩31.53bn₩30.40bn₩22.67bn₩20.63bn₩26.72bn₩24.71bn
Operating income−₩2.95bn−₩2.92bn₩1.04bn₩5.73bn−₩4.61bn−₩1.18bn₩572.9m₩134.3m
Net income₩2.13bn₩112.8m−₩3.33bn₩5.73bn−₩10.89bn−₩1.58bn−₩2.85bn−₩2.68bn
Diluted earnings per share14.420.76-22.5438.75-73.98-11.39-20.50-19.30
Cash from operations—−₩1.87bn−₩4.08bn−₩4.04bn−₩383.0m−₩2.51bn₩290.0m₩4.14bn
Capital spending—−₩13.03bn−₩8.82bn−₩10.03bn−₩11.44bn−₩2.73bn−₩31.75bn−₩27.32bn
Free cash flow—−₩14.90bn−₩12.90bn−₩14.07bn−₩11.82bn−₩5.24bn−₩31.46bn−₩23.19bn
Total assets₩320.07bn₩319.33bn₩305.96bn₩307.70bn₩307.55bn₩306.21bn₩303.44bn₩304.72bn
Cash and short-term investments—————₩74.94bn₩76.79bn₩82.84bn
Debt₩43.50bn₩41.50bn——₩11.07bn₩11.85bn₩36.56bn₩24.37bn
Shareholders' equity₩204.30bn₩201.72bn₩201.55bn₩204.41bn₩197.06bn₩187.98bn₩189.54bn₩196.03bn

Financial ratios

Data as of 3 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating margin-3.5%2.5%7.6%3.2%4.6%0.9%———
Net margin-9.6%2.7%6.9%-0.5%4.6%0.3%———
Return on equity-5.0%1.4%3.4%-0.2%1.7%0.1%———
Return on assets-3.3%0.9%2.7%-0.2%1.6%0.1%———
Free cash flow yield———————4.7%33.7%
Revenue growth6.2%5.5%14.2%18.3%7.8%10.0%———
Earnings growth-474.0%-58.3%-1763.2%-112.3%1372.3%-93.0%———
Current ratio0.92x1.81x4.72x6.17x9.14x10.70x———
Debt to equity—0.19x0.13x0.03x0.00x0.00x0.00x——
Equity ratio65.9%62.5%78.6%86.7%92.7%92.7%———
Interest coverage-1.17x1.00x89.29x173.62x152.32x24.25x———
R&D as a share of sales1.0%1.5%2.3%4.0%4.9%4.8%———
Buybacks as a share of market value———————-811.8%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue8.6%10.3%14.6%
Operating income——-0.4%
Net income196.1%—10.7%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-0.6%2.3%2.4%2.3%
Net margin-3.6%-0.3%0.4%1.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-272.6——-7693.6————262.5—
Price to sales26.124.835.636.376.7124.5100.792.317.9104.8

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2-for-1 split · 28 Aug 2007
  • 3-to-1 reverse split · 18 Aug 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.